Oxford Investment Consultants

Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Oxford Quantum Circuits specializes in quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company has developed a fully functional quantum computer that integrates control systems, hardware, and software, enabling customers to streamline operations and explore innovative solutions. Their unique superconducting circuits are designed to maintain high qubit quality and control, which is essential for achieving commercially viable processing power. By leveraging this advanced technology, Oxford Quantum Circuits supports a range of applications, from pioneering new battery technologies to facilitating life-changing discoveries in medicine.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Living Optics Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the design and development of compact hyperspectral imaging cameras and related software. The company's innovative technology captures data that is not visible to the human eye or traditional cameras, making hyperspectral imaging more accessible and affordable for a variety of applications in consumer products, medical devices, and the manufacturing industry. Living Optics aims to empower computer vision developers and scientists by providing portable solutions that enable the integration of spectral imaging data into new research and applications. In September 2022, the company secured $25 million in Series A funding to further its mission of revolutionizing the imaging market.

Oxford Quantum Circuits specializes in quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company has developed a fully functional quantum computer that integrates control systems, hardware, and software, enabling customers to streamline operations and explore innovative solutions. Their unique superconducting circuits are designed to maintain high qubit quality and control, which is essential for achieving commercially viable processing power. By leveraging this advanced technology, Oxford Quantum Circuits supports a range of applications, from pioneering new battery technologies to facilitating life-changing discoveries in medicine.

Salience Labs specializes in developing hybrid photonic-electronic chips tailored for artificial intelligence applications. Originating from extensive research at the University of Oxford and the University of Münster, the company focuses on silicon photonics to meet the increasing demands of AI workloads in data center infrastructure. Its flagship product, an optical switch, enables all-optical networking between computing nodes, effectively addressing data movement bottlenecks. By utilizing photons instead of electrons for data processing, Salience Labs' technology significantly reduces power consumption while enhancing processing speeds. This innovative approach aims to transform the hardware landscape necessary for maximizing AI capabilities, providing low-latency, high-bandwidth networking that accelerates job completion and lowers operational costs.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.

Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Sphere Fluidics Limited is a life sciences company focused on developing innovative technologies for single-cell analysis and characterization. The company offers specialized cell analysis systems that facilitate the discovery of new cell strains and molecules, aiding scientists in screening for and isolating rare biological variants. Their products serve various applications, including research, therapeutic development, bioproduction, and diagnostics. By providing collaborative research and development services, Sphere Fluidics aims to help clients enhance efficiency, reduce costs, and accelerate advancements in biological and biopharmaceutical discovery.

OrthoSon Limited is a medical device company based in Oxford, United Kingdom, focused on developing a minimally-invasive treatment for chronic low back pain. Established in 2015, the company has created a novel bio-structural gel implant that is injected into the nucleus of the intervertebral disc. This innovative procedure follows the natural fissures of degeneration, allowing the gel to restore the disc's mechanical function and alleviate pain. By providing a motion-preserving alternative to traditional spinal fusion techniques, OrthoSon aims to offer patients a safe and effective option that takes less than 30 minutes and does not require incisions.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Oxford Biotrans Limited is a company based in Abingdon, United Kingdom, that focuses on the development and commercialization of high-value chemical compounds through enzyme technology. Established in 2013, it leverages patented cytochrome P450 enzyme technology to create products such as Nootkatone, a naturally derived flavor and fragrance from Valencene, a citrus extract. The company aims to introduce innovative enzymatic routes for producing specialty chemicals, with initial offerings centered on flavors and fragrances. Additionally, the technology has broader applications in the production of pheromones, pharmaceuticals, and other specialty chemicals. With over 15 years of research backing its initiatives, Oxford Biotrans is committed to providing environmentally friendly ingredients that minimize chemical waste and energy consumption.

Diffblue Limited, based in Oxford, United Kingdom, specializes in artificial intelligence software that automates various coding tasks, primarily focusing on enhancing Java development through automated testing solutions. Founded in 2016 as a spin-out from the AI research group at Oxford, Diffblue's technology autonomously generates unit tests, which helps developers save time and ensure software robustness. The software not only creates fully formed tests guaranteed to compile and run, but also identifies and fixes bugs, refactors code, and maintains regression tests. By providing insights into test coverage, code testability, and complexity, Diffblue aims to transform the software development process, making it more efficient and less error-prone.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, focused on developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, which is a significant contributor to osteoarthritis, affecting over 300 million individuals worldwide. The company's flagship product, FibroFix, is a hydrogel biomaterial designed to mimic human knee cartilage, offering solutions for repairing both meniscal and articular cartilage. FibroFix Meniscus and FibroFix Cartilage are specifically tailored to restore function and integrate seamlessly with the body's tissues, promoting rapid recovery and improved mobility. Orthox is preparing to enter clinical trials for its lead product and plans to expand the application of its technology to other joints, as well as explore advancements beyond orthopaedics. With the global biomaterials market projected to exceed $250 billion by 2025, Orthox is well-positioned to capitalize on the growing demand for innovative and effective solutions in joint health.

Agilent Raman Spectroscopy’s proprietary technologies use novel variants of Raman spectroscopy. Their instruments can rapidly and accurately identify materials hidden inside objects or through opaque barriers such as plastic, coloured glass, paper and skin, or can measure the concentrations of materials in mixtures, with a high degree of accuracy. Agilent Raman Spectroscopy is formerly known as Cobalt Light Systems and is part of Agilent.